Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.

Conditions

• Pompe Disease
• Glycogen Storage Disease Type II (GSD II)
• Acid Maltase Deficiency

Interventions

• DRUG: GZ402666

Sponsor

Genzyme, a Sanofi Company